文献速递糖尿病肥胖与代谢综合征

皮下注射替尔泊肽与司美格鲁肽治疗成人2型糖尿病:随机对照试验的系统综述与网络Meta分析

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
PubMed 文献 · Diabetologia · 2024-04-13

该系统综述与网络Meta分析纳入28项随机对照试验共23,622例2型糖尿病成人,比较皮下注射替尔泊肽与司美格鲁肽的疗效与安全性;替尔泊肽15 mg降低HbA1c和体重最显著,且各剂量替尔泊肽减重均优于对应剂量司美格鲁肽,两药均增加胃肠道不良事件但不增加严重不良事件或严重低血糖风险。

要点

  • 替尔泊肽15 mg降低HbA1c最显著(较安慰剂平均差-21.61 mmol/mol [-1.96%])。
  • 替尔泊肽各剂量降HbA1c与司美格鲁肽2.0 mg相当,优于司美格鲁肽1.0 mg和0.5 mg。
  • 替尔泊肽减重优于司美格鲁肽,15 mg较安慰剂减重9.57 kg。

核心结论

  • 皮下注射替尔泊肽在降低HbA1c和体重方面较皮下注射司美格鲁肽对2型糖尿病患者效果更显著。
  • 两药均增加胃肠道不良事件,尤其替尔泊肽较高剂量。

研究设计与样本

  • 系统综述与网络Meta分析,检索PubMed和Cochrane截至2023年11月11日。
  • 纳入28项随机对照试验,共23,622例受试者(女性44.2%),干预时长至少12周。
  • 比较替尔泊肽5 mg、10 mg或15 mg每周一次与司美格鲁肽0.5 mg、1.0 mg或2.0 mg每周一次,或与安慰剂或其他降糖药对照。
  • 采用Cochrane偏倚风险工具第2版(ROB 2)评估偏倚风险,频率学随机效应网络Meta分析,CINeMA框架评估证据置信度。
  • PROSPERO注册号CRD42022382594。

主要发现

  • 较安慰剂,替尔泊肽15 mg降低HbA1c最有效(平均差-21.61 mmol/mol [-1.96%]),其次为替尔泊肽10 mg(-20.19 mmol/mol [-1.84%])、司美格鲁肽2.0 mg(-17.74 mmol/mol [-1.59%])、替尔泊肽5 mg(-17.60 mmol/mol [-1.60%])、司美格鲁肽1.0 mg(-15.25 mmol/mol [-1.39%])和司美格鲁肽0.5 mg(-12.00 mmol/mol [-1.09%])。
  • 药物间比较,替尔泊肽各剂量与司美格鲁肽2.0 mg相当,优于司美格鲁肽1.0 mg和0.5 mg。
  • 较安慰剂,替尔泊肽减重效果优于司美格鲁肽,替尔泊肽减重范围从9.57 kg(15 mg)至5.27 kg(5 mg),司美格鲁肽减重范围从4.97 kg(2.0 mg)至2.52 kg(0.5 mg)。
  • 药物间比较,替尔泊肽15 mg、10 mg和5 mg减重效果分别优于司美格鲁肽2.0 mg、1.0 mg和0.5 mg。
  • 两药较安慰剂均增加胃肠道不良事件发生率,但替尔泊肽和司美格鲁肽均未增加严重不良事件或严重低血糖风险。

关键数值与推荐

  • 主要结局为HbA1c和体重较基线的变化。
  • 次要结局包括达到HbA1c≤48 mmol/mol(≤6.5%)或<53 mmol/mol(<7.0%)、体重减轻至少10%,以及安全性结局包括胃肠道不良事件和严重低血糖。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus. METHODS: We searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in adults with type 2 diabetes, regardless of background glucose-lowering treatment. Eligible trials compared any of the specified doses of tirzepatide and semaglutide against each other, placebo or other glucose-lowering drugs. Primary outcomes were changes in HbA1c and body weight from baseline. Secondary outcomes were achievement of HbA1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia. We used version 2 of the Cochrane risk-of-bias tool (ROB 2) to assess the risk of bias, conducted frequentist random-effects network meta-analyses and evaluated confidence in effect estimates utilising the Confidence In Network Meta-Analysis (CINeMA) framework. RESULTS: A total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA1c (mean difference -21.61 mmol/mol [-1.96%]) followed by tirzepatide 10 mg (-20.19 mmol/mol [-1.84%]), semaglutide 2.0 mg (-17.74 mmol/mol [-1.59%]), tirzepatide 5 mg (-17.60 mmol/mol [-1.60%]), semaglutide 1.0 mg (-15.25 mmol/mol [-1.39%]) and semaglutide 0.5 mg (-12.00 mmol/mol [-1.09%]). In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg. Compared with placebo, tirzepatide was more efficacious than semaglutide for reducing body weight, with reductions ranging from 9.57 kg (tirzepatide 15 mg) to 5.27 kg (tirzepatide 5 mg). Semaglutide had a less pronounced effect, with reductions ranging from 4.97 kg (semaglutide 2.0 mg) to 2.52 kg (semaglutide 0.5 mg). In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively. Both drugs increased incidence of gastrointestinal adverse events compared with placebo, while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia. CONCLUSIONS/INTERPRETATION: Our data show that s.c. tirzepatide had a more pronounced effect on HbA1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events. REGISTRATION: PROSPERO registration no. CRD42022382594.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024. PMID: 38613667. doi:10.1007/s00125-024-06144-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。